Racetam

Aniracetam is a fat-soluble piracetam analog that positively modulates AMPA glutamate receptors. It was marketed in Italy and Japan for dementia and post-stroke cognitive symptoms, and placebo-controlled trials in Alzheimer-type dementia gave contradictory answers. It is no longer in clinical use, and in healthy animals it does nothing measurable.

Coluracetam, originally MKC-231, is the one racetam with a genuinely distinct mechanism: it enhances high-affinity choline uptake by acting on the choline transporter CHT1 itself. Everything known about it comes from rodents with chemically lesioned cholinergic neurons. No human trial with a published abstract is cited here.

Fasoracetam is a racetam repurposed as a metabotropic glutamate receptor activator and trialed in adolescents with ADHD who carry disruptive variants in mGluR network genes. A 30-patient open-label dose-escalation study with one single-blind placebo week reported significant improvement on global rating scales and good tolerability. That is a phase I result and the only human efficacy evidence there is.

Nefiracetam is a Japanese piracetam derivative that potentiates nicotinic α4β2 and NMDA receptors at nanomolar concentrations, through Gs proteins and protein kinase C. Its human testing went in an unexpected direction — post-stroke depression and apathy rather than memory — and the results were mixed at best: no overall antidepressant effect in 159 patients, a positive apathy signal in one trial and nothing in a second that could only randomize 13.

Noopept is a Russian dipeptide designed to mimic the piracetam pharmacophore, reported active at doses about a thousandth of piracetam's. It is a prodrug: the parent is undetectable in rat brain an hour after dosing, and the active species is cycloprolylglycine, a peptide the brain already makes. Its clinical evidence is Russian, small and uncontrolled, and its primary molecular action appears to be stabilization of HIF-1.

Oxiracetam is the 4-hydroxy analog of piracetam, prescribed for decades in Italy and South Korea for cognitive impairment. Small trials from the late 1980s and early 1990s reported benefit in mild dementia, but a 500-patient trial published in 2026 found no effect whatsoever on post-stroke cognition. South Korea's regulator recommended suspending prescriptions in January 2023.

Phenylpiracetam is a Soviet-era piracetam analog with a phenyl ring on the pyrrolidone, developed in 1983 and prescribed in Russia as Phenotropil. Modern work identifies the dopamine transporter as its only significant molecular target, and the two enantiomers do different things. It was the first nootropic banned in sport, in 1998. Its human evidence is substantial but almost entirely Russian and non-randomized: a matched 400-patient stroke-rehabilitation study, a 56-patient comparison against piracetam and a 1170-patient observational program.

Piracetam is the original "nootropic". C. Giurgea developed it in the late 1960s and coined the word to describe it. It is licensed in several countries for cognitive disorders, vertigo and cortical myoclonus. The evidence is mixed. An older meta-analysis found a global benefit in older adults with cognitive impairment, but a 2024 meta-analysis could not confirm an effect on memory.

Pramiracetam is a Parke-Davis piracetam derivative with a basic diisopropylaminoethyl side chain, far more potent than piracetam in animal amnesia models. Its two positive controlled human results are narrow: partial reversal of scopolamine-induced amnesia in healthy volunteers and improved delayed recall in young men with memory problems after head injury or anoxia. In Alzheimer's disease it did nothing.